Theoretically, disruption of bcr-abl fusion gene would disturb its translation into BCR-ABL protein, thus thoroughly settle the problem of CML initiation and drug resistance. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.